Analyst Says Sequencing-Based Dx Could Be 'Ultimate Opportunity' for Illumina
June 08, 2011
Analyst Says Sequencing-Based Dx Could Be 'Ultimate Opportunity' for Illumina
According to investment firm William Blair & Company, Illumina sees its largest diagnostic opportunity in the cancer space, using its MiSeq for targeted sequencing of oncology markers. To support this application, it plans to pursue 510(k) certification for the platform in 2012.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Transgenomic Launches NGS-Based Mitochondrial Disease Test, Developing Autism Risk Test
June 21, 2011 / Clinical Sequencing News - Q&A: Matt Posard on Illumina's Clinically Focused Business Unit
March 14, 2012 / Clinical Sequencing News - NIPT and Cancer Drive Illumina's Clinical Business in Q1 as it Looks to Launch Fetal Aneuploidy IVD
April 24, 2013 / Clinical Sequencing News - Analysts Increase Valuations, Upgrade Illumina
January 4, 2013 / GenomeWeb Daily News - Oxford Group Launches PGM-Based Cancer Test under UK's Stratified Medicine Program
January 2, 2013 / Clinical Sequencing News